N Engl J Med 392(6):612615 Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T (2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
The GLP-1 Administration Experience Dosage Guidelines GLP-1 is administered through a weekly subcutaneous injection, offering the convenience of self-treatment at home or supervised in-office administration
Patients should speak with a medical provider before using any GLP-1, GIP/GLP-1, or future triple-agonist medication
Incretin effect is essential for the postprandial glucose controls, as it is responsible for 5070% of insulin secretion after oral glucose intake in non-diabetic subjects 1
Stay hydrated and eat small, frequent meals to reduce nausea